CoChat

Exploring the screening capacity of the Fear of Cancer Recurrence Inventory‐Short Form for clinical levels of fear of cancer recurrence

Fardell, Joanna E., Jones, Georden, Smith, Allan Ben, Lebel, Sophie, Thewes, Belinda, Costa, Daniel, Tiller, Kerry, Simard, Sébastien, Feldstain, Andrea, Beattie, Sara, McCallum, Megan, on behalf of the Conquer Fear authorship group, Butow, Phyllis · 2018 · Psycho-Oncology
Cited by 130

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objective: Fear of cancer recurrence (FCR) is a common concern among cancer survivors. Identifying survivors with clinically significant FCR requires validated screening measures and clinical cut‐offs. We evaluated the Fear of Cancer Recurrence Inventory‐Short Form (FCRI‐SF) clinical cut‐off in 2 samples. Methods: Level of FCR in study 1 participants (from an Australian randomized controlled trial: ConquerFear) was compared with FCRI‐SF scores. Based on a biopsychosocial interview, clinicians rated participants as having nonclinical, subclinical, or clinical FCR. Study 2 participants (from a Canadian FCRI‐English validation study) were classified as having clinical or nonclinical FCR by using the semistructured clinical interview for FCR (SIFCR). Receiver operating characteristic analyses evaluated the screening ability of the FCRI‐SF against clinician ratings (study 1) and the SIFCR (study 2). Results: In study 1, 167 cancer survivors (mean age: 53 years, SD = 10.1) participated. Clinicians rated 43% as having clinical FCR. In study 2, 40 cancer survivors (mean age: 68 years, SD = 7.0) participated; 25% met criteria for clinical FCR according to the SIFCR. For both studies 1 and 2, receiver operating characteristic analyses suggested a cut‐off ≥22 on the FCRI‐SF identified cancer survivors with clinical levels of FCR with adequate sensitivity and specificity. Conclusions: Establishing clinical cut‐offs on FCR screening measures is crucial to tailoring individual care and conducting rigorous research. Our results suggest using a higher cut‐off on the FCRI‐SF than previously reported to identify clinically significant FCR. Continued evaluation and validation of the FCRI‐SF cut‐off is required across diverse cancer populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pon.4516

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 16

  1. 10.1002/pon.1346 · DOI · Paper page
  2. 10.1007/s00520-007-0296-x · DOI
  3. Simard S, 2009, Screening and comorbidity of clinical fear of cancer recurrence, Psycho‐Oncol, 18, 171
  4. 10.1002/pon.3430 · DOI · Paper page
  5. 10.1007/s11764-014-0383-1 · DOI
  6. Herman S, 2013, Screening Dysfunctional Fear of Cancer Recurrence in Breast Cancer Patients Wishing for Psychological Help: The Validity of the Fear of Cancer Recurrence Inventory (FCRI)
  7. 10.1007/s00520-015-2943-y · DOI
  8. 10.1002/(SICI)1099-1611(199706)6:2<95::AID-PON250>3.0.CO;2-B · doi:10.1002/(sici)1099-1611(199706)6:2<95::aid-pon250>3.0.co;2-b
  9. 10.1097/NCC.0b013e3182813a17 · DOI · Paper page
  10. 10.1007/s10549-016-3730-2 · DOI
  11. 10.1002/pon.4103 · DOI
  12. 10.1002/pon.1481 · DOI · Paper page
  13. 10.1037/a0030186 · DOI
  14. 10.1007/s10865-013-9537-2 · DOI
  15. 10.1016/S0936-6555(97)80055-6 · DOI · Paper page
  16. 10.1111/j.1365-2354.2006.00722.x · DOI · Paper page

Cited by

Metadata

Authors
Fardell, J. E., Jones, G., Smith, A. B., Lebel, S., Thewes, B., Costa, D., Tiller, K., Simard, S., Feldstain, A., Beattie, S., McCallum, M., on behalf of the Conquer Fear authorship group, & Butow, P.
Venue
Psycho-Oncology
Publisher
Wiley
Published
2017-08-18
Volume
27
Issue
2
Pages
492-499
ISSN
  • 1057-9249 (ISSN-L)
  • 1099-1611
OpenAlex
W2742135261
Cited by
130
References
15
FWCI
3.55
Type
journal article
Language
en
Open access
closed
Funders
  • beyondblue
  • National Breast Cancer Foundation
  • Cancer Australia (CAPdCCRS 1022584)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.